Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares KNSA
$78.13
+1.15%
at last close
Market Cap$6.03 billion
P/E Ratio78.92
Div Yield—
Volume451.6K
52-Week Range
$32.89$82.94
Analyst Ratings
- Consensus
- Buy — 8 Buy · 0 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $87.38 (+11.8% upside)
Key Stats
- Today's Range
- $75.90 – $78.73
- 50-Day Range
- $60.06 – $82.94
- 52-Week Range
- $32.89 – $82.94
- Volume
- 452K shs
- Average Volume
- 503K shs
- Market Cap
- $6.03 billion
- P/E Ratio
- 78.92
- Dividend Yield
- —
Valuation
- P/E Ratio
- 78.92
- Price / Book
- 9.21
- Price / Sales
- 7.17
Short Interest
- Short Interest
- 0.02%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $840.85 million
- Net Income
- $80.66 million
- Net Margin
- 9.59%
- Return on Equity
- 12.33%
- Debt-to-Equity
- —
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Related Stocks
Compare head-to-head: KNSA vs LLY·KNSA vs JNJ·KNSA vs ABBV·KNSA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.